Table 5 Comparison of Proseek® values obtained from women with early stage ovarian cancer versus benign disease
From: A multiplex platform for the identification of ovarian cancer biomarkers
Protein | Early versus benign | |||
|---|---|---|---|---|
AUC (95% CI) | Rank | Sensitivity at 95% specificity (95% CI) | Rank | |
HE4 | 0.87 (0.76, 0.96) | 1 | 0.6 (0.37, 0.88) | 1 |
CA.125 | 0.87 (0.73, 0.97) | 2 | 0.46 (0.13, 0.93) | 3 |
hK11 | 0.79 (0.67, 0.89) | 3 | 0.38 (0.15, 0.65) | 9 |
PRSS8 | 0.78 (0.64, 0.89) | 4 | 0.44 (0.2, 0.7) | 4 |
IL.6 | 0.75 (0.65, 0.86) | 5 | 0.54 (0.28, 0.7) | 2 |
MK | 0.72 (0.57, 0.85) | 6 | 0.37 (0.13, 0.61) | 11 |
CXCL13 | 0.71 (0.53, 0.85) | 7 | 0.39 (0.16, 0.66) | 7 |
CXCL10 | 0.71 (0.57, 0.85) | 8 | 0.35 (0.14, 0.62) | 13 |
EZR | 0.7 (0.55, 0.83) | 9 | 0.33 (0.11, 0.56) | 14 |
CSTB | 0.7 (0.53, 0.85) | 10 | 0.21 (0.01, 0.62) | 23 |
FR.alpha | 0.69 (0.56, 0.81) | 11 | 0.39 (0.08, 0.62) | 8 |
VEGF.A | 0.69 (0.52, 0.84) | 12 | 0.37 (0.19, 0.6) | 10 |
KLK6 | 0.69 (0.54, 0.8) | 13 | 0.41 (0.11, 0.63) | 5 |
FUR | 0.68 (0.53, 0.83) | 14 | 0.16 (0.04, 0.42) | 34 |
CSF.1 | 0.68 (0.5, 0.83) | 15 | 0.14 (0.01, 0.41) | 42 |
AM | 0.68 (0.5, 0.82) | 16 | 0.26 (0.07, 0.54) | 18 |
LYN | 0.67 (0.56, 0.79) | 17 | 0.39 (0.05, 0.59) | 6 |
ICOSLG | 0.67 (0.51, 0.82) | 18 | 0.19 (0.02, 0.47) | 28 |
CDH3 | 0.67 (0.51, 0.83) | 19 | 0.35 (0.21, 0.6) | 12 |
CXCL9 | 0.66 (0.49, 0.82) | 20 | 0.28 (0.09, 0.57) | 16 |
ILT.3 | 0.66 (0.5, 0.82) | 21 | 0.17 (0.02, 0.49) | 32 |
GDF.15 | 0.66 (0.49, 0.84) | 22 | 0.1 (0, 0.54) | 51 |
IFN.gamma | 0.65 (0.5, 0.79) | 23 | 0.26 (0.01, 0.55) | 17 |
EGFR | 0.65 (0.49, 0.8) | 24 | 0.1 (0.01, 0.37) | 56 |
MCP.1 | 0.65 (0.48, 0.81) | 25 | 0.09 (0, 0.36) | 58 |